ABSTRACT In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBF_α_/_β_ genes impairs normal hematopoietic differentiation and is supposed to cooperate with

additional mutations promoting proliferation. The incidence and the prognosis of receptor tyrosine kinase (RTK) _c-Kit_ and _FLT3_ mutations and _Ras_ mutations were evaluated in 103

pediatric and adult patients with CBF-AML. _c-Kit_ mutations were present in 17% patients. _c-Kit_ exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 versus 6%). Only

one patient had _FLT3_-ITD but _FLT3_-D835 was as frequent as reported in AML population (7%). _Ras_ mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 versus

patients. As previously observed, _Ras_ mutations did not affect prognosis. Screening for RTK mutations may help to identify patients with a more adverse outcome and thus susceptible to

benefit from intensified protocols or RTK inhibitors. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS

Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS GENOMIC LANDSCAPE OF PATIENTS WITH _FLT3_-MUTATED ACUTE MYELOID LEUKEMIA (AML)

TREATED WITHIN THE CALGB 10603/RATIFY TRIAL Article Open access 03 August 2022 CHARACTERISTICS AND OUTCOMES OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WITH _KMT2A_ REARRANGEMENTS Article 09

May 2025 DISTINCT CLINICO-BIOLOGICAL FEATURES IN AML PATIENTS WITH LOW ALLELIC RATIO _FLT3_-ITD: ROLE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST REMISSION Article 20 October 2021

REFERENCES * Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R _et al_. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute

myeloid leukemia varies by cytogenetic subtype. _Cancer Res_ 1998; 58: 4173–4179. CAS  PubMed  Google Scholar  * Marcucci G, Caligiuri MA, Bloomfield CD . Molecular and clinical advances in

core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. _Cancer Invest_ 2000; 18: 768–780. Article  CAS  PubMed  Google Scholar  *

Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC _et al_. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and

overall survival in adult patients with _de novo_ acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). _Blood_ 2002; 100: 4325–4336. Article  CAS  PubMed  Google

Scholar  * Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A _et al_. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161

cases from the French AML Intergroup. _Blood_ 2002; 99: 3517–3523. Article  CAS  PubMed  Google Scholar  * Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F _et al_. Prognosis

of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. _Blood_ 2003; 102: 462–469. Article  CAS  PubMed  Google Scholar  * Schlenk RF, Benner

A, Krauter J, Buchner T, Sauerland C, Ehninger G _et al_. Individual patient data-based meta-analysis of patients aged 16–60 years with core binding factor acute myeloid leukemia: a survey

of the German Acute Myeloid Leukemia Intergroup. _J Clin Oncol_ 2004; 22: 3741–3750. Article  CAS  PubMed  Google Scholar  * Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees

JH _et al_. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. _Br J Haematol_ 2002;

118: 385–400. Article  PubMed  Google Scholar  * Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B _et al_. Allogeneic compared with autologous stem cell transplantation in the

treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. _Blood_ 2003;

102: 1232–1240. Article  CAS  PubMed  Google Scholar  * Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F _et al_. Early allogeneic stem-cell transplantation for young adults

with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. _J Clin Oncol_ 2005; 23: 7676–7684. Article  PubMed  Google

Scholar  * Kelly LM, Gilliland DG . Genetics of myeloid leukemias. _Annu Rev Genomics Hum Genet_ 2002; 3: 179–198. Article  CAS  PubMed  Google Scholar  * Bowen DT, Frew ME, Hills R, Gale

RE, Wheatley K, Groves MJ _et al_. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

_Blood_ 2005; 106: 2113–2119. Article  CAS  PubMed  Google Scholar  * Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D _et al_. c-kit protooncogene exon 8 in-frame deletion plus

insertion mutations in acute myeloid leukaemia. _Br J Haematol_ 1999; 105: 894–900. Article  CAS  PubMed  Google Scholar  * Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort

WM, Wilson GA _et al_. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. _Br J Haematol_ 2003; 121: 775–777. Article  CAS  PubMed 

Google Scholar  * Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F _et al_. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and

identification of an internal tandem duplication. _Haematologica_ 2004; 89: 920–925. CAS  PubMed  Google Scholar  * Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H _et al_.

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). _Leukemia_ 2005; 19:

1361–1366. Article  CAS  PubMed  Google Scholar  * Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX _et al_. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in

stepwise leukemogenesis and response to Gleevec. _Proc Natl Acad Sci USA_ 2005; 102: 1104–1109. Article  CAS  PubMed  PubMed Central  Google Scholar  * Goemans BF, Zwaan Ch M, Miller M,

Zimmermann M, Harlow A, Meshinchi S _et al_. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. _Leukemia_ 2005; 19: 1536–1542. Article 

CAS  PubMed  Google Scholar  * Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K _et al_. KIT-D816 mutations in AML1-ETO positive AML are associated with impaired

event-free and overall survival. _Blood_ 2006; 107: 1791–1799. Article  CAS  PubMed  Google Scholar  * Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M _et al_. KIT mutations, and

not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study

Group. _Blood_ 2006; 107: 1806–1809. Article  CAS  PubMed  Google Scholar  * Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB _et al_. Prognostic impact of c-KIT mutations in

core binding factor leukemias. An Italian retrospective study. _Blood_ 2005, doi:10.1182/blood-2005-1109-3640. * Perel Y, Auvrignon A, Leblanc T, Michel G, Reguerre Y, Vannier JP _et al_.

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucemie Aigue

Myeloblastique Enfant) Cooperative Group. _Leukemia_ 2005; 19: 2082–2089. Article  CAS  PubMed  Google Scholar  * Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H _et

al_. Randomized comparison of double induction and timed-sequential induction to a ‘3+7’ induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000

study. _Blood_ 2004; 104: 2467–2474. Article  CAS  PubMed  Google Scholar  * Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X _et al_. Prognostic significance of FLT3

internal tandem repeat in patients with _de novo_ acute myeloid leukemia treated with reinforced courses of chemotherapy. _Leukemia_ 2002; 16: 1699–1704. Article  CAS  PubMed  Google Scholar

  * Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S _et al_. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. _Blood_ 1999; 93: 3074–3080. CAS 

PubMed  Google Scholar  * Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S _et al_. Prognostic implication of FLT3 and Ras gene mutations in patients with acute

promyelocytic leukemia (APL): a retrospective study from the European APL Group. _Leukemia_ 2005; 19: 1153–1160. Article  CAS  PubMed  Google Scholar  * Kottaridis PD, Gale RE, Linch DC .

Flt3 mutations and leukaemia. _Br J Haematol_ 2003; 122: 523–538. Article  CAS  PubMed  Google Scholar  * Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T . Prognostic significance of FLT3

internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. _Leukemia_ 2005; 19: 1345–1349. Article  CAS  PubMed  Google Scholar  * Cairoli

R, Beghini A, Morello E, Grillo G, Montillo M, Larizza L _et al_. Imatinib mesylate in the treatment of core binding factor leukemias with KIT mutations. A report of three cases. _Leuk Res_

2005; 29: 397–400. Article  CAS  PubMed  Google Scholar  * Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N . Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16)

and a C-KIT exon 8 mutation. _Leukemia_ 2005; 19: 1673–1675. Article  CAS  PubMed  Google Scholar  * Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W _et al_. Extracellular KIT

receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. _Blood_ 2005; 106: 3958–3961. Article  CAS  PubMed  Google Scholar  *

Leroy H, de Botton S, Grardel-Duflos N, Darre S, Leleu X, Roumier C _et al_. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). _Leukemia_ 2005; 19: 367–372.

Article  CAS  PubMed  Google Scholar  * Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W _et al_. Prognostic value of minimal residual disease quantification by real-time reverse

transcriptase polymerase chain reaction in patients with core binding factor leukemias. _J Clin Oncol_ 2003; 21: 4413–4422. Article  CAS  PubMed  Google Scholar  * Buonamici S, Ottaviani E,

Testoni N, Montefusco V, Visani G, Bonifazi F _et al_. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse

and may identify patients in a curable state. _Blood_ 2002; 99: 443–449. Article  CAS  PubMed  Google Scholar  * Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA _et al_.

Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. _Blood_ 2000; 95: 815–819.

CAS  PubMed  Google Scholar  * Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W . New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid

leukemia based on quantification of fusion transcripts. _Blood_ 2003; 102: 2746–2755. Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This work was supported by

the Canceropole Nord-ouest (Axe onco-hématologie) and by The STIC 2005. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France N

Boissel, E Raffoux & H Dombret * Laboratoire d'Hématologie A, Hôpital Calmettes, Lille, France H Leroy, N Philippe & C Preudhomme * Service d'Hématologie Pédiatrique,

Hôpital Saint-Louis, Paris, France B Brethon, T Leblanc & A Baruchel * Service des Maladies du Sang, CHU de Lille, Lille, France S de Botton & B Quesnel * Service

d'Onco-hématologie pédiatrique, Hôpital Trousseau, Paris, France A Auvrignon & G Leverger * Service d'Hématologie Clinique, Hôpital Edouard Herriot, Lyon, France X Thomas *

Service d'Hématologie, Hôpital Necker, Paris, France O Hermine Authors * N Boissel View author publications You can also search for this author inPubMed Google Scholar * H Leroy View

author publications You can also search for this author inPubMed Google Scholar * B Brethon View author publications You can also search for this author inPubMed Google Scholar * N Philippe

View author publications You can also search for this author inPubMed Google Scholar * S de Botton View author publications You can also search for this author inPubMed Google Scholar * A

Auvrignon View author publications You can also search for this author inPubMed Google Scholar * E Raffoux View author publications You can also search for this author inPubMed Google

Scholar * T Leblanc View author publications You can also search for this author inPubMed Google Scholar * X Thomas View author publications You can also search for this author inPubMed 

Google Scholar * O Hermine View author publications You can also search for this author inPubMed Google Scholar * B Quesnel View author publications You can also search for this author

inPubMed Google Scholar * A Baruchel View author publications You can also search for this author inPubMed Google Scholar * G Leverger View author publications You can also search for this

author inPubMed Google Scholar * H Dombret View author publications You can also search for this author inPubMed Google Scholar * C Preudhomme View author publications You can also search

for this author inPubMed Google Scholar CONSORTIA FOR THE ACUTE LEUKEMIA FRENCH ASSOCIATION (ALFA) AND THE LEUCÉMIES AIGUËS MYÉLOBLASTIQUES DE L'ENFANT (LAME) COOPERATIVE GROUPS

CORRESPONDING AUTHOR Correspondence to C Preudhomme. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Boissel, N., Leroy, H., Brethon, B. _et al._

Incidence and prognostic impact of _c-Kit_, _FLT3_, and _Ras_ gene mutations in core binding factor acute myeloid leukemia (CBF-AML). _Leukemia_ 20, 965–970 (2006).

https://doi.org/10.1038/sj.leu.2404188 Download citation * Received: 24 September 2005 * Revised: 03 February 2006 * Accepted: 14 February 2006 * Published: 06 April 2006 * Issue Date: 01

June 2006 * DOI: https://doi.org/10.1038/sj.leu.2404188 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * acute myeloid leukemia * gene mutations *

prognosis